Is ImmunoGen Running Out of Steam, or Taking a Breather?
There's good news and bad news for ImmunoGen (NASDAQ: IMGN) shareholders. The good news is that the biotech stock is up more than 230% so far in 2017. The bad news? Shares have dropped nearly 20% in the last couple of weeks.
Certainly, ImmunoGen's tremendous performance this year outweighs its recent decline. But is ImmunoGen now running out of steam -- or is it just taking a breather?
Source: Fool.com
Immunogen Inc. Aktie
28,97 €
0,07 %